NASDAQ$LAB
Standard Biotool · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Revenue decreased by 8 percent, and the company focused on COVID-19 related opportunities.
Fluidigm Corporation reported a decrease in revenue for the first quarter of 2020, but is focusing on new opportunities related to COVID-19, including testing infrastructure and immune response measurement.
- First quarter revenue decreased 8% to $27.6 million.
- The company is focused on protecting employees, repositioning products for COVID-19 applications, and managing liquidity.
- Fluidigm's Biomark system is being used for high-throughput COVID-19 testing.
- The mass cytometry platform is measuring immune response in COVID-19 treatments and characterization.
Headline financials
Revenue & EPS history
Standard Biotool · Revenue · Quarterly
$27.6M
Forward guidance
The company anticipates infectious disease applications will complement their long-term commitment to biomarker discovery, disease research, and treatment paradigms linked to understanding immune function and response in a wide range of diseases.
Tailwinds
- Labs can process up to 6,000 samples per day using the Biomark system.
- The company is well-positioned to support testing of investigational new vaccines and therapeutics.
- The core business model remains intact.
- There are incremental opportunities for new growth in the infectious disease market.
- Infectious disease applications will complement the long-term commitment to biomarker discovery.
Headwinds
- The pandemic has created near-term headwinds.
- Lower average selling prices.
- Unfavorable product mix.
- Fixed amortization over lower revenue.
- Evolving market conditions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
-2.7%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+0.6%
Avg return
30 days after
42%
19 / 45 earnings
Positive
+44.5%
Q3 2015
Best reaction
-51.0%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | +1.0% | +16.3% | |
| Q4 2025 | +2.6% | -4.3% | -21.7% | |
| Q3 2025 | -2.6% | +0.0% | +26.1% | |
| Q1 2025 | -3.9% | +9.4% | +0.0% | |
| Q4 2024 | -10.3% | -9.4% | -2.6% | |
| Q3 2024 | +12.0% | +5.7% | -13.7% | |
| Q2 2024 | -38.8% | -31.5% | -8.2% | |
| Q1 2024 | +1.7% | +4.6% | -2.1% | |
| Q4 2023 | -3.8% | +10.3% | +15.8% | |
| Q3 2023 | -6.9% | +6.9% | +15.2% | |
| Q2 2023 | +6.7% | +20.0% | +20.8% | |
| Q1 2023 | +9.1% | +7.3% | +33.9% | |
| Q4 2022 | +0.0% | -0.5% | +3.3% | |
| Q3 2022 | -7.9% | +32.7% | +29.7% | |
| Q2 2022 | -11.1% | -6.9% | -22.8% | |
| Q1 2022 | -5.8% | -21.4% | -37.1% | |
| Q4 2021 | +3.1% | -1.4% | +8.0% | |
| Q3 2021 | -5.1% | +0.8% | -8.2% | |
| Q2 2021 | -7.0% | -0.7% | +4.7% | |
| Q1 2021 | +5.1% | +12.5% | +12.1% | |
| Q4 2020 | -19.8% | -20.5% | -35.2% | |
| Q3 2020 | +13.5% | -18.2% | -7.7% | |
| Q2 2020 | +2.6% | +0.1% | -17.3% | |
| Q1 2020 | +15.9% | +31.9% | +0.0% | |
| Q4 2019 | -0.3% | -3.7% | -30.6% | |
| Q3 2019 | -51.0% | -54.5% | -51.0% | |
| Q2 2019 | -31.5% | -40.0% | -52.5% | |
| Q1 2019 | -10.4% | -13.2% | -1.4% | |
| Q4 2018 | +10.4% | +17.5% | +37.4% | |
| Q3 2018 | +2.1% | +1.7% | +13.9% | |
| Q2 2018 | +7.0% | +8.4% | +26.1% | |
| Q1 2018 | -2.2% | -7.1% | -5.3% | |
| Q4 2017 | +13.4% | +30.3% | +17.8% | |
| Q3 2017 | +1.8% | -7.4% | +4.7% | |
| Q2 2017 | -3.1% | -4.9% | +44.9% | |
| Q1 2017 | +17.3% | +16.1% | -3.6% | |
| Q4 2016 | -1.6% | +0.3% | -18.1% | |
| Q3 2016 | -1.8% | +11.1% | +48.8% | |
| Q2 2016 | -12.2% | -13.4% | -15.8% | |
| Q1 2016 | +5.4% | — | — | |
| Q4 2015 | +0.0% | — | — | |
| Q3 2015 | +44.5% | — | — | |
| Q2 2015 | -35.8% | — | — | |
| Q1 2015 | -26.4% | — | — | |
| Q4 2014 | +2.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro